Skip to main content
SpringerLink
Log in

Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogs

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

CI-994 (acetyldinaline) is an orally active anticancer drug currently in Phase 1 clinical trials. To assess int preclinical toxicity, CI-994 was administered orally as suspensions to Wistar rats (10/sex/dose) and in capsules to beagle dogs (3/sex/dose) once daily for two weeks. Doses were 1.5,5, and 15 mg/kg for rats (9,30, and 90 mg/m2, respectively), and 0.5, 2, and 5 mg/kg for dogs (10,40 and 100 mg/m2, respectively) systemic exposure was dose-proportional based on toxicokinetic analysis in dogs. Severe clinical signs and mortality occurred at the highest dose in both species beginning on Day 10. Neutropenia, lymphocytopenia, thrombocytopenia, lymphoid depletion, bone marrow hypocellularity, and testicular degeneration were observed in both species, primarily at the mid- and high-dosed. Despite cotinued treatment, neutrophil counts in dogs returned to control levels in Week 2. Othere microscopic findings in rats included splenic hematopoietic depletion at all doses and epithelial cell necrosis in various tissues at 15 mg/kg. Additional bone marrow changes in dogs involved myeloid and megakaryocyte hyperplasia at 2 mg/kg and abnomal myeloid and megakaryocyte maturation at 2 and 5 mg/kg. Except for the testicular efficts in both species, all chages were reversible within a 4- week (rat) or 9- week (dog) recovery period. The results of these studies show that target organ effects of CI-944 principally involve tissues with rapidly dividing cell populations and that bone marrow suppression is the dose-limiting toxicity. CI-944 also seems to interfere with the release and/or maturation of cells in the bone marrow.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berger MR, Richter H, Seelig MH, Eibl H, Schmähl D: New cytostatics — more activity and less toxicity. Cancer Treat Rev 17:143–154, 1990

    Article  PubMed  CAS  Google Scholar 

  2. Howard CT, Roberts BJ, Vincent PW, Elliott WL: N-acetyl-dinaline. A small molecule with in vivo cytostatic activity. Proc Am Assoc Cancer Res 33:393, 1992

    Google Scholar 

  3. Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Lowichik N, Biernat L, Foster B, Wozniak A, Lisow L, Valdivieso M, Baker L, Leopold W, Sebolt J, Bissery M-C, Mattes K, Dzubow J, Rake J, Perni R, Wentland M, Coughlin S, Shaw JM, Liversidge G, Liversidge E, Bruno J, Sarpotdar P, Moore R, Patterson G: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacog 33:102–122, 1995

    Article  CAS  Google Scholar 

  4. LoRusso PM, Demchik L, Foster B, Knight J, Bissery M-C, Polin LM, Leopold WR, Corbett TH: Preclinical activity of CI-994 (acetyldinaline; PD 123654). Invest. New Drugs 14:349–356, 1996

    Article  PubMed  CAS  Google Scholar 

  5. El-Beltagi HM, Martens ACM, Lelieveld P, Haroun EA, Hagenbeek A: Acctyldinaline: a new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells — preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Res 53:3008–3014, 1993

    PubMed  CAS  Google Scholar 

  6. El-Beltagi HM, Martens ACM, Dahab GM, Hagenbeek A: Efficacy of acetyldinaline for treatment of minimal residual disease (MRD): Preclinical studies in the BNML rat model for human acute myelocytic leukemia. Leukemia 7:1795–1800, 1993

    PubMed  CAS  Google Scholar 

  7. Kraker AJ, Wolven A, Fry DW, Klohs WD: Cell cycle and nucleotide metabolism effects of 4-(acetylamino)-N-(2-aminophenyl)benzamide (PD 123654, Goe 5549) in HCT-8 cells. Proc Am Assoc Cancer Res 32:396, 1991

    Google Scholar 

  8. Caldwell J: Conjugation reactions of nitrogen centers. In: Jakoby WB, Bend JR, Caldwell J (eds) Metabolic Basis of Detoxification. Academic Press, New York, 1982, pp 291–306

    Google Scholar 

  9. Berger MR, Klenner T, Schmähl D, Weiershausen U: Influence of 4-amino-N-(2′-aminophenyl)benzamide (GOE 1734) on cAMP levels in mammary carcinoma, plasma, heart, and liver of methylnitrosourea-(MNU)induced SD rats, Proc Am Assoc Cancer Res 29:503, 1988

    Google Scholar 

  10. Berger MR, Schmähl D: Influence of 4-amino-N(2′-aminophenyl)benzamide on sex steroid receptor levels in methylnitrosourea-induced rat mammary carcinoma. Proc Am Assoc Cancer Res 30:560, 1989

    Google Scholar 

  11. Berger MR, Gebelein M: Influence of dinaline on nucleotides in rat mammary carcinoma cells. Proc Am Assoc Cancer Res 32:400, 1991

    Google Scholar 

  12. Klohs W, Kraker A, Steinkampf R, Moore C, Dominick M: Mitochondrial involvement in the mechanism of action of the novel antiturnor compound 4-(acetylamino)-N-(2-aminophenyl)benzamide (PD 123654, Goe 5549). Proc Am Assoc Caucer Res 32:396, 1991

    Google Scholar 

  13. Leopold WR, Hook KE, Fry DW: Activity and biochemical properties of Goe 1734 (PD 104208), an anticancer agent with a novel mechanism of activity. Proc Am Assoc Cancer Res 28:302, 1987

    Google Scholar 

  14. Kraker AJ, Moore CW: Activity and effects of 4-amino-N-(2-aminophenyl)benzamide (Goe 1734, PD 104208), a compound with novel mechanisms of action. Proc Am Assoc Cancer Res 30:584, 1989

    Google Scholar 

  15. Wulf G, Falk H, Weiershausen U, Valet G: Antimetabolic and cytostatic potential of 4-amino-N-(2′-aminophenyl)-benzamide (dinaline) on adriamycin-sensitive and resistent Friend leukemia cells. J Cancer Res Clin Oncol 115:S42, 1989

    Google Scholar 

  16. Valet G, Wulf G, Weiershausen U: Cytostatic action of dinaline (4-amino-N-(2-aminophenyl)-benzamide) as determined by flow cytometry. Cytometry Suppl 4:33, 1990

    Google Scholar 

  17. Rummel SA, Kraker AJ, Steinkampf RW, Hook KE, Klohs WD: Role of a small molecular weight phosphoprotein in the mechanism of action of Cl-994 (N-acetyldinaline). Int J Cancer 62:636–642, 1995

    Article  PubMed  CAS  Google Scholar 

  18. Berger MR, Garzon F, Zeller WJ, Schmähl D: Anticancer activity of 4-amino-N-(2′-aminophenyl)benzamide (GOE 1834) in autochthonous rat colonic tumors and in transplanted MXT mouse mammary carcinoma. Proc Am Assoc Cancer Res 27:284, 1986

    Google Scholar 

  19. Berger MR, Bischoff H, Fritschi E, Henne T, Herrmann M, Pool B-L, Satzinger G, Schmähl D, Weiershausen U: Synthesis, toxicity, and therapeutic efficacy of 4-amino-N-(2′-aminophenyl)benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep 69:1415–1424, 1985

    PubMed  CAS  Google Scholar 

  20. Department of Health and Human Services: Guide for the care and use of laboratory animals. NIH Publication No. 86-23, revised 1985

  21. Animal Welfare Act. Code of Federal Regulations (CFR), Title opportunity to study human toxicology. In: Powis G, Hacker MP (eds) The Toxicity of Anticancer Drugs. Pergamon, New York, 1991, pp 1–9

  22. Moser M-H, Paukovits WR: Haemoprotection against cytostatic drugs by stem cell inhibition. Trends Pharmacol Sci 12:304–310, 1991

    Article  PubMed  CAS  Google Scholar 

  23. Kaneko JJ: Porphyrins and porphyrias. In: Kaneko JJ (ed) Clinical Biochemistry of Domestic Animals. Academic Press, San Diego, 1989, pp 235–255

    Google Scholar 

  24. Harker LA: Regulation of thrombopoiesis. Am J Physiol 218:1376–1380, 1970

    PubMed  CAS  Google Scholar 

  25. Kuter DJ, Rosenburg RD: Regulation of megakaryoeyte ploidy in vivo in the rat. Blood 75:74–81, 1990

    PubMed  CAS  Google Scholar 

  26. Yarrington JT, Wallace CD, Loudy DE, Gibson JP: Three-month effects of MDL 19,660 on the caiüne platelet and erythrocyte. Fund Appl Toxicol 18:247–254, 1992

    Article  CAS  Google Scholar 

  27. Testa NG, Hendry JH, Molineux G: Long-term bone marrow damage after cytotoxic treatment. Hematology 8:75–91, 1988

    Google Scholar 

  28. Nolte T, Harleman JH, Jahn W: Histopathology of chemically induced testicular atrophy in rats. Exptl Toxic Pathol 47:267–286, 1995

    Article  CAS  Google Scholar 

  29. Graziano MJ, Kim S-N, MacDonald JR, Watkins JR: Toxicity of the anticancer folate antagonist trimetrexate in rats. Fund Appl Toxicol 18:115–125, 1992

    Article  CAS  Google Scholar 

  30. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD: Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats, and dogs. Anti-Cancer Drugs 5:579–590, 1994

    Article  PubMed  CAS  Google Scholar 

  31. Pegg DG, Watkins JR, Graziano MJ, McKenna MJ: Subchronic intravenous toxicity of the antineoplastic drug, amsacrine, in male Wistar rats. Fund Appl Toxicol 32:45–52, 1996

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pathology and Experimental Toxicology, Ann Arbor, Michgan, USA

    Michael J. Graziano, GaryD. Pilcher, Kathleen M. Walsh, Olajide B. Kasalil & Louis Radulovic

Authors
  1. Michael J. Graziano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. GaryD. Pilcher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathleen M. Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olajide B. Kasalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Louis Radulovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graziano, M.J., Pilcher, G., Walsh, K.M. et al. Preclinical toxicity of a new oral anticancer drug, CI-994 (Acetyldinaline), in rats and dogs. Invest New Drugs 15, 295–310 (1997). https://doi.org/10.1023/A:1005937502511

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005937502511

Search

Navigation